1-7 of 7
Lourenia Cassoli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inequity in travel burden among patients receiving bispecific antibodies (BsAbs) for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): A real-world study of Medicare beneficiaries in the United States (US)

Free
Zachary Frosch, Anthony Masaquel, Esprit Ma, Eric Zuk, Matthew Davis, Fadoua El Moustaid, Mei Wu, Carolina Reyes, Lourenia Cassoli, Scott Huntington
Journal: Blood
Blood (2025) 146 (Supplement 1): 2622.
https://doi.org/10.1182/blood-2025-2622
Published: 2025
Journal Articles

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Free
Ajay Major, Esprit Ma, Anthony Masaquel, Mazie Tsang, Mengyang Di, Supreet Kaur, Priyanka Pophali, Sally Werner, Rebecca Bungay, Dominick Latremouille-Viau, Annie Guerin, Carolina Reyes, Mei Wu, Lourenia Cassoli, Pallawi Torka
Journal: Blood
Blood (2025) 146 (Supplement 1): 6181.
https://doi.org/10.1182/blood-2025-6181
Published: 2025
Journal Articles

Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) preferred fixed-duration treatments with less frequent administrations in the era of novel bispecific antibodies (BsAbs)

Free
Zachary Frosch, Anthony Masaquel, David Fox, Carolina Reyes, Lourenia Cassoli, Dominic Lai, Kelley Myers, Cooper Bussberg, Krish Patel
Journal: Blood
Blood (2025) 146 (Supplement 1): 6179.
https://doi.org/10.1182/blood-2025-6179
Published: 2025
Journal Articles

A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab

Free
Pallawi Torka, Anthony Masaquel, Lourenia Cassoli, David Fox, Arliene Mangalindan, Ajay Major
Journal: Blood
Blood (2024) 144 (Supplement 1): 3647.
https://doi.org/10.1182/blood-2024-198476
Published: 2024
Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

Free
David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 3646.
https://doi.org/10.1182/blood-2024-198451
Published: 2024
Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Free
Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch
Journal: Blood
Blood (2024) 144 (Supplement 1): 782.
https://doi.org/10.1182/blood-2024-198414
Published: 2024
Journal Articles

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

Free
David Fox, Fadoua El Moustaid, Anthony Masaquel, Katherine L Rosettie, Hazal Celik, Lourenia Cassoli, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 5027.
https://doi.org/10.1182/blood-2024-198461
Published: 2024